One-Dose drug clears severe psoriasis pustules in days
NCT ID NCT03782792
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 26 times
Summary
This study tested a single intravenous dose of spesolimab in 53 adults with generalized pustular psoriasis (GPP) experiencing a moderate-to-severe flare. The main goal was to see if the drug could clear visible pustules within one week compared to a placebo. Results showed that spesolimab rapidly reduced pustules, offering a new option for controlling sudden, serious flares of this rare skin condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
2nd Affiliated Hosp Zhejiang University College of Medical
Hangzhou, 310009, China
-
Asahikawa Medical University Hospital
Hokkaido, Asahikawa, 078-8510, Japan
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Farhat Hached Hospital
Sousse, 4000, Tunisia
-
Fukuoka University Hospital
Fukuoka, Fukuoka, 814-0180, Japan
-
HOP Robert Debré
Reims, 51092, France
-
HOP Saint-André
Bordeaux, 33000, France
-
HOP Saint-Louis
Paris, 75010, France
-
Hedi Chaker Hospital, Department of Dermatology
Tunisia, 1053, Tunisia
-
Hospital Kuala Lumpur
Kuala Lumpur, 50586, Malaysia
-
Hospital Pakar Sultanah Fatimah
Muar town, 84000, Malaysia
-
Hospital Pulau Pinang
Pulau Pinang, 10990, Malaysia
-
Hospital Raja Permaisuri Bainun
Negeri Perak/Ipoh, 30450, Malaysia
-
Hospital Selayang
Kuala Selangor, 68100, Malaysia
-
Hospital Sultan Ismail
Johor Bahru, 81100, Malaysia
-
Hospital Sultanah Aminah
Johor Bahru, 80100, Malaysia
-
Huashan Hospital, Fudan University
Shanghai, 200040, China
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Klinikum der Universität München - Campus Innenstadt
München, 80337, Germany
-
La Rabta Hospital
Tunis, 1007, Tunisia
-
Nagoya City University Hospital
Aichi, Nagoya, 467-8602, Japan
-
National Taiwan University Hospital
Taipei, 10016, Taiwan
-
National University Hospital
Singapore, 119074, Singapore
-
Ramathibodi Hospital
Ratchatewi, Bangkok, 10400, Thailand
-
Severance Hospital
Seoul, 03722, South Korea
-
Shanghai Skin Disease Hospital
Shanghai, 200000, China
-
The First Hospital of Dalian Medical University
Dalian, 116011, China
-
Tianjin Medical University General Hospital
Tianjin, 30052, China
-
Tohoku University Hospital
Miyagi, Sendai, 980-8574, Japan
-
Tokyo Medical University Hachioji Medical Center
Tokyo, Hachioji, 193-0998, Japan
-
Tokyo Medical University Hospital
Tokyo, Shinjuku-ku, 160-0023, Japan
-
University Hospital of Lausanne
Lausanne, 1011, Switzerland
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Miami
Miami, Florida, 33125, United States
-
University of South Florida
Tampa, Florida, 33612, United States
-
Universitätsklinikum Bonn AöR
Bonn, 53127, Germany
-
Universitätsklinikum Essen AöR
Essen, 45147, Germany
Conditions
Explore the condition pages connected to this study.